In pancreatic cancer, time weighs more than many words. One year often becomes a ruthless measure, a threshold that arrives too quickly, a line that doctors look at with caution and families with bated breath. This is why the data released now deserve real attention: an experimental drug called elraglusib, used together with standard chemotherapy, showed a concrete advantage in a phase 2 clinical study published in Nature Medicine.
The study involved 233 patients with metastatic pancreatic cancer treated in 60 centers in six countries in North America and Europe. Participants were divided between those receiving standard chemotherapy alone and those receiving the same therapy plus elraglusib. In the group treated with the combination, the median survival rose to 10.1 months, compared to 7.2 months in the group treated with chemotherapy alone. Statistically, this translates into a 38% reduction in the risk of death.
The most striking data, however, comes from the twelve-month threshold, which in metastatic pancreatic cancer remains one of the hardest to cross. Among patients who received elraglusib along with chemotherapy, 44.1% were still alive at one year. In the group treated only with chemotherapy the share stopped at 22.3%. Even later, the gap remained visible: at 24 months, 13.2% of patients in the elraglusib arm were alive, while in the other group that figure dropped to zero.
An important milestone
Those three extra months, read like this, may seem like a short step. Inside a clinical study on the pancreas they have another weight. The researchers themselves explain that the trial also included patients with a disease that had progressed very rapidly, therefore with less chance of really benefiting from the treatment. Looking at the patients who responded best, the impact appeared much clearer.
Elraglusib was born from the work of researchers at Northwestern University and acts on the GSK-3 beta protein, considered important both for tumor growth and for the mechanisms by which the tumor is able to slow down the immune response. In the published work, the authors describe a manageable safety profile: the side effects observed were largely consistent with those of chemotherapy, although a little more frequent in the group receiving the experimental drug. The most common include a drop in white blood cells, tiredness and temporary changes in vision, described as reversible.
Researchers urge you to keep your feet firmly planted on the ground. These are encouraging results, yet to be confirmed in phase 3 studies, therefore larger and more decisive. However, one fact remains that is difficult to ignore: in one of the most aggressive and difficult to treat tumors, such a clear sign of survival rarely arrives. For those who experience such a diagnosis, and for those around them, it is already a concrete glimmer of hope.
You might also be interested in:
